Company: CERO
Filing Date: 2025-05-02
Form Type: PRER14A
Source: 0001213900-25-039149
Chunk: 77

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-02
Form: PRER14A
Chunk 77
---
 San Francisco, CA 94080. We will forward by U.S. mail any such communication to each director, and the chairman of the board of directors in his capacity as a representative of the board of directors, to whom such communication is addressed to the address specified by each such director and the chair of the board of directors, unless there are safety or security concerns that mitigate against further transmission. A copy of any such written communication may also be forwarded to our general counsel and a copy of such communication may be retained for a reasonable period of time. You may submit your concern anonymously or confidentially. Communications may be forwarded to other directors if they relate to important substantive matters and include suggestions or comments that may be important for other directors to know. In general, communications relating to corporate governance and long -termcorporate strategy are more likely to be forwarded than communications relating to ordinary business affairs, personal grievances and matters as to which we tend to receive repetitive or duplicative communications. 43

DIRECTOR COMPENSATION None of our directors received compensation in 2024 for services rendered to PBAX or Legacy CERo, with the exception of Dr. Corey, who was compensated for his service as our Chief Executive Officer. Dr. Corey was a named executive officer and his compensation is provided in the “ 2024 Summary Compensation Table” below. On March 25, 2024, the board of directors approved the compensation for non -employeedirectors for 2024. Each non -employeedirector will receive $30,000 per annum, paid quarterly in advance. In addition, each non -employeedirector other than the vice chairman received an option award to purchase 1,125shares of common stock. Such option awards vest quarterly over a three -yearperiod and expire ten years after the grant date. The vice chairman will receive $150,000 per annum, paid quarterly in advance. In addition, the vice chairman received an option award to purchase 5,272shares of common stock. Such option awards vest quarterly over a three -yearperiod and expire ten years after the grant date. The awards to the vice chairman were forfeited in connection with his appointment as Interim Chairman and Chief Executive Officer on October 1, 2024. On September 30, 2024, the board of directors approved the grant of 2,550 options to each of our non -employeedirectors, which will vest (i) 50% upon the FDA’s acceptance of our IND and (ii) 50